Studies have found that EGCG could inhibit the growth of androgen-sensitive human prostate cancer cells (PCA) in a dose-dependent manner, and this effect may be mediated by G0/G1 phase cell cycle arrest caused by WAF1/p21 [51]. Here, CDKN1A is linked to prostate carcinoma.